Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Base de datos
Tópicos
Tipo del documento
Intervalo de año
1.
Braz Oral Res ; 37: e038, 2023.
Artículo en Inglés | MEDLINE | ID: covidwho-2317980

RESUMEN

Accumulated evidence has shown that the oral cavity may be an important reservoir for SARS-CoV-2. Some authors have suggested that the use of mouthrinses could reduce SARS-CoV-2 viral load in the saliva. Thus, the aim of this review was to synthesize evidence about the efficacy of mouthrinses in reducing the salivary viral load of SARS-CoV-2. 2. Nine randomized controlled trials (RCTs) have investigated the efficacy of different mouthrinses in reducing salivary SARS-CoV-2 loads. Various active ingredients have been tested in these trials: 0.5%,1% and 2% povidone-iodine, 0.2% and 0.12% chlorhexidine (CHX), 0.075% cetylpyridinium chloride (CPC), 0.075% CPC with Zinc lactate, 1% and 1.5% hydrogen peroxide (HP), 1.5% HP + 0.12% CHX and ß-cyclodextrin and citrox. The studies reported an intra-group reduction in the salivary levels of the virus, when compared with the baseline. However, the majority of these trials failed to demonstrate a significant inter-group difference between active groups and the control group relative to the decrease in salivary SARS-CoV-2 loads. Although promising, these results should be confirmed by larger trials.


Asunto(s)
Antiinfecciosos Locales , COVID-19 , Humanos , SARS-CoV-2 , Antisépticos Bucales/uso terapéutico , COVID-19/prevención & control , Clorhexidina , Boca , Peróxido de Hidrógeno , Cetilpiridinio/uso terapéutico , Antiinfecciosos Locales/uso terapéutico
2.
MMWR Morb Mortal Wkly Rep ; 71(33): 1065-1068, 2022 Aug 19.
Artículo en Inglés | MEDLINE | ID: covidwho-1994638

RESUMEN

On July 18, 2022, the New York State Department of Health (NYSDOH) notified CDC of detection of poliovirus type 2 in stool specimens from an unvaccinated immunocompetent young adult from Rockland County, New York, who was experiencing acute flaccid weakness. The patient initially experienced fever, neck stiffness, gastrointestinal symptoms, and limb weakness. The patient was hospitalized with possible acute flaccid myelitis (AFM). Vaccine-derived poliovirus type 2 (VDPV2) was detected in stool specimens obtained on days 11 and 12 after initial symptom onset. To date, related Sabin-like type 2 polioviruses have been detected in wastewater* in the patient's county of residence and in neighboring Orange County up to 25 days before (from samples originally collected for SARS-CoV-2 wastewater monitoring) and 41 days after the patient's symptom onset. The last U.S. case of polio caused by wild poliovirus occurred in 1979, and the World Health Organization Region of the Americas was declared polio-free in 1994. This report describes the second identification of community transmission of poliovirus in the United States since 1979; the previous instance, in 2005, was a type 1 VDPV (1). The occurrence of this case, combined with the identification of poliovirus in wastewater in neighboring Orange County, underscores the importance of maintaining high vaccination coverage to prevent paralytic polio in persons of all ages.


Asunto(s)
COVID-19 , Poliomielitis , Vacuna Antipolio Oral , Poliovirus , Humanos , New York/epidemiología , Poliomielitis/epidemiología , Poliomielitis/prevención & control , Vacuna Antipolio Oral/efectos adversos , Salud Pública , SARS-CoV-2 , Aguas Residuales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA